华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02552 华领医药-B

已收盘 12-23 16:08:41

1.520

-0.010

-0.65%

最高1.540	最低1.500	成交量47.40万
今开1.500	昨收1.530	日振幅2.61%
总市值16.04亿	流通市值16.04亿	总股本10.56亿
成交额71.82万	换手率0.04%	流通股本10.56亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02552","market":"HK","secType":"STK","nameCN":"华领医药-B","latestPrice":1.52,"timestamp":1734941321011,"preClose":1.53,"halted":0,"volume":474000,"delay":0,"floatShares":1055588761,"shares":1055588761,"eps":-0.22978486,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.01,"latestTime":"12-23 16:08:41","open":1.5,"high":1.54,"low":1.5,"amount":718240,"amplitude":0.026144,"askPrice":1.53,"askSize":52000,"bidPrice":1.52,"bidSize":59500,"shortable":0,"etf":0,"ttmEps":-0.2855384679035943,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"listingDate":1536854400000,"adjPreClose":1.53,"openAndCloseTimeList":[[1734917400000,1734926400000],[1734930000000,1734940800000]],"volumeRatio":0.831142,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02552","defaultTab":"news","newsList":[{"id":"2490716873","title":"荣获年度卓越大健康企业，华领医药-B(02552.HK)进入价值成长红利期","url":"https://stock-news.laohu8.com/highlight/detail?id=2490716873","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490716873?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:06","pubTimestamp":1733987199,"startTime":"0","endTime":"0","summary":"华领医药的糖尿病药物正瞄准了大健康中最具有广泛性的代表领域...","market":"hk","thumbnail":"https://img7.gelonghui.com/column/5.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1470755","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","BK1574","02552"],"gpt_icon":0},{"id":"2489427221","title":"第九届格隆汇全球投资嘉年华之“金格奖”重磅揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2489427221","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489427221?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:18","pubTimestamp":1733458698,"startTime":"0","endTime":"0","summary":"这些公司榜上有名！","market":"sg","thumbnail":"https://img2.gelonghui.com/e78a7-7d7798c2-3ae5-4401-98c9-c45da0f03932.jpg?guru_height=1067&guru_width=1600","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/e78a7-7d7798c2-3ae5-4401-98c9-c45da0f03932.jpg?guru_height=1067&guru_width=1600"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1439915","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06996","01450","01105","00688","03978","02279","02362","00033","02522","00206","01675","00182","08279","06058","00322","02105","00697","01458","02552","06833","09699","02533","02018","06989","01405","06828","06993","03709","00382","01725","03738","09878","01519","03633","01070","03306","02400","06609","03311","06078","01969","01258","01448","02499","02517","09959","02128","00992","02273","01769"],"gpt_icon":0},{"id":"2489863244","title":"华领医药-B(02552)上涨5.0%，报1.47元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489863244","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489863244?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:21","pubTimestamp":1733383263,"startTime":"0","endTime":"0","summary":"12月5日，华领医药-B(02552)盘中上涨5.0%，截至15:21，报1.47元/股，成交223.77万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司，其核心产品华堂宁，也即多格列艾汀片，已于2022年9月30日获得中国国家药品监督管理局的上市批准，主要用于治疗2型糖尿病。华领医药的未来发展断点涵盖新产品上市、新市场开拓和新疾病领域三个维度，期望在全球范围内推动医药创新。截至2024年中报，华领医药-B营业总收入1.03亿元、净利润-1.42亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/05152146047724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2489065439","title":"华领医药-B盘中异动 下午盘股价大涨5.00%报1.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489065439","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489065439?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:20","pubTimestamp":1733383254,"startTime":"0","endTime":"0","summary":"2024年12月05日下午盘15时20分，华领医药-B股票出现异动，股价急速拉升5.00%。截至发稿，该股报1.470港元/股，成交量158.15万股，换手率0.15%，振幅6.43%。资金方面，该股资金流入121.778万港元，流出98.736万港元。机构评级方面，在所有2家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。华领医药-B股票所在的生物技术行业中，整体跌幅为1.03%。华领医药-B公司简介：华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120515205498e58a1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120515205498e58a1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2489109192","title":"华领医药：临床研究与行业机遇并驱，多格列艾汀开启商业新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2489109192","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489109192?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:56","pubTimestamp":1733363816,"startTime":"0","endTime":"0","summary":"年终大戏上演，美联储降息如约而至，巧遇中国创新药领域火力全开，临床捷报如雨后春笋，政策红利更是锦上添花。这股行业春风里，生物科技、创新药成为投行2025年投资策略中重点关注方向之一。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202412_1/2e6a9187-05ab-406a-a07d-c5d2d564efbc.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202412_1/2e6a9187-05ab-406a-a07d-c5d2d564efbc.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67510868bde0b340822c3be5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2488614882","title":"华领医药(02552.HK)完成两项药物研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2488614882","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488614882?lang=zh_cn&edition=full","pubTime":"2024-12-02 09:57","pubTimestamp":1733104620,"startTime":"0","endTime":"0","summary":"华领医药发新闻稿指，早前在第九届中国医药创新与投资大会上宣布，已成功完成在美国开展的第二代葡萄糖激酶激活剂的临床研究。据介绍，相关临床研究设计为每日一次口服给药，旨在通过缓释技术来延长药物在体内的作用时间、改善患者依从性、延长刺激肠道内GLP-1分泌效果。另外，华领医药同日亦宣布，已成功完成与香港中文大学合作开展SENSITIZE研究，该研究为多格列艾汀改善β细胞葡萄糖敏感性的作用机制研究。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240201104559354_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240201104559354_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400937/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2487572049","title":"华领医药宣布成功完成在中国香港开展的SENSITIZE研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2487572049","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487572049?lang=zh_cn&edition=full","pubTime":"2024-11-30 17:23","pubTimestamp":1732958580,"startTime":"0","endTime":"0","summary":"上海2024年11月30日 /美通社/ -- 华领医药今天在第九届中国医药创新与投资大会上宣布，公司已经成功完成与香港中文大学Juliana Chan教授团队合作开展SENSITIZE研究，该研究为多格列艾汀改善β细胞葡萄糖敏感性的作用机制研究。此次报告的SENSITIZE 2研究结果显示，采用高葡萄糖钳夹技术，多格列艾汀单次给药修复GK酶活性，显著改善葡萄糖耐量异常人群的二相胰岛素分泌和β细胞葡萄糖敏感性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4568862_ZH68862_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","02552","GK","BK4085","IH","BK1191","BK4510","BK4150","IGT","BK4563"],"gpt_icon":0},{"id":"2487041572","title":"华领医药宣布成功完成在美国开展的第二代葡萄糖激酶激活剂I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2487041572","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487041572?lang=zh_cn&edition=full","pubTime":"2024-11-30 17:23","pubTimestamp":1732958580,"startTime":"0","endTime":"0","summary":"上海2024年11月30日 /美通社/ -- 华领医药今天在第九届中国医药创新与投资大会上宣布，已经成功完成在美国开展的第二代葡萄糖激酶激活剂的Ia临床研究。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。2022年9月30日，华堂宁已获得中国国家药品监督管理局的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4568861_ZH68861_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2487940785","title":"华领医药与拜耳“分手”","url":"https://stock-news.laohu8.com/highlight/detail?id=2487940785","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487940785?lang=zh_cn&edition=full","pubTime":"2024-11-30 03:53","pubTimestamp":1732909983,"startTime":"0","endTime":"0","summary":"本报记者 陈婷 曹学平 深圳报道历时4年，一场围绕“全球首创”国产新药的合作戛然而止。日前，华领医药（2552.HK）公告向拜耳医药保健有限公司（以下简称“拜耳”）发出书面通知，表示有意自2025年1月1日起，将公司开发用于治疗2型糖尿病的多格列艾汀（dorzagliatin，商品名为“华堂宁”）在中国的商业化责任过渡至公司自身...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241130A00OFJ00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241130A00OFJ00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1191","BK1574","02552"],"gpt_icon":0},{"id":"2486186789","title":"华领医药-B(02552)上涨6.82%，报1.41元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486186789","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486186789?lang=zh_cn&edition=full","pubTime":"2024-11-27 10:56","pubTimestamp":1732676218,"startTime":"0","endTime":"0","summary":"11月27日，华领医药-B(02552)盘中上涨6.82%，截至10:56，报1.41元/股，成交100.2万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司，其核心产品华堂宁，也即多格列艾汀片，已于2022年9月30日获得中国国家药品监督管理局的上市批准，主要用于治疗2型糖尿病。华领医药的未来发展断点涵盖新产品上市、新市场开拓和新疾病领域三个维度，期望在全球范围内推动医药创新。截至2024年中报，华领医药-B营业总收入1.03亿元、净利润-1.42亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/27105645732370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2486861516","title":"华领医药-B盘中异动 早盘股价大涨5.30%报1.390港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486861516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486861516?lang=zh_cn&edition=full","pubTime":"2024-11-27 10:23","pubTimestamp":1732674219,"startTime":"0","endTime":"0","summary":"2024年11月27日早盘10时23分，华领医药-B股票出现波动，股价快速拉升5.30%。截至发稿，该股报1.390港元/股，成交量25.15万股，换手率0.02%，振幅5.30%。资金方面，该股资金流入24.715万港元，流出9.3025万港元。华领医药-B股票所在的生物技术行业中，整体涨幅为1.09%。其相关个股中，科济药业-B、诺诚健华、华领医药-B涨幅较大，振幅较大的相关个股有科济药业-B、来凯医药-B、北海康成-B，振幅分别为19.83%、13.53%、11.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127102339a2588fad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127102339a2588fad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2485051882","title":"华领医药与拜耳“分手”背后：合作药物纳入医保后已降价超六成","url":"https://stock-news.laohu8.com/highlight/detail?id=2485051882","media":"每日经济新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485051882?lang=zh_cn&edition=full","pubTime":"2024-11-23 20:34","pubTimestamp":1732365240,"startTime":"0","endTime":"0","summary":"11月22日，华领医药-B（02552.HK，股价1.32港元，市值13.93亿港元）公告称，其全资附属公司向拜耳医药保健有限公司（以下简称拜耳）发出书面通知，表示有意自2025年1月1日起，将公司开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂多格列艾汀（商品名：华堂宁）在中国的商业化责任过渡至华领医药。公告称，为实现过渡，华领医药有权并计划自2025年1月1日起终止协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411233248797314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411233248797314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2485297192","title":"里程碑付款已约15亿元，拜耳、华领医药各奔前程？","url":"https://stock-news.laohu8.com/highlight/detail?id=2485297192","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485297192?lang=zh_cn&edition=full","pubTime":"2024-11-23 11:41","pubTimestamp":1732333269,"startTime":"0","endTime":"0","summary":"日前，华领医药发布公告显示，其全资附属公司华领医药技术（上海）有限公司向拜耳发出书面通知，表示有意从2025年1月1日起，将本公司开发的用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁?（多格列艾汀片）在中国的商业化责任过渡至本公司。华领医药方面称，“从公告日期起到终止生效日期为止，拜耳与本公司将继续履行协议项下的义务，并承诺启动一个友好的、以患者为中心的过渡计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411233248750284.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411233248750284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1574","02552"],"gpt_icon":0},{"id":"2485526485","title":"超40亿元里程碑付款还没收到一半，华领医药和拜耳分手了","url":"https://stock-news.laohu8.com/highlight/detail?id=2485526485","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485526485?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:46","pubTimestamp":1732286760,"startTime":"0","endTime":"0","summary":"华堂宁是华领医药唯一商业化的产品，在被纳入国家医保药品目录后，华领医药股价和毛利率均大受拖累。根据协议条款，华领医药可获得额外最高可达41.8亿元的销售里程碑付款。自与拜耳合作以来，华堂宁已达成数个相关的里程碑，华领医药也因此获得丰厚的回报。华领医药称，随着多格列艾汀的生产规模扩大，公司预计毛利率将会上升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-22/doc-incwycqa3764056.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-22/doc-incwycqa3764056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","02552"],"gpt_icon":0},{"id":"2485044268","title":"与华领医药半道分手 拜耳“血亏”超10亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2485044268","media":"经济观察报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485044268?lang=zh_cn&edition=full","pubTime":"2024-11-22 21:28","pubTimestamp":1732282106,"startTime":"0","endTime":"0","summary":"经济观察网 记者 张铃 11月22日，华领医药（02552.HK）发布公告，已于11月21日向拜耳发出书面通知，自2025年1月1日起，将收回其开发的糖尿病药品华堂宁在中国的商业化权益。在外界看来，华领医药与拜耳这一合作终止得很突然。就在两周前的进博会上，拜耳集团处方药事业部副总裁、中国医学部负责人李瑶在接受媒体采访时，还...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OVoOnwSPrwujzgrnOfyveEGg1TXsHQ-XVC_bJsvUYwL5kAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OVoOnwSPrwujzgrnOfyveEGg1TXsHQ-XVC_bJsvUYwL5kAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241122A09ILT00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241122A09ILT00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2485251701","title":"华领医药与拜耳“分手”，收回糖尿病药物商业化权益，已获里程碑付款15亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485251701","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485251701?lang=zh_cn&edition=full","pubTime":"2024-11-22 20:07","pubTimestamp":1732277229,"startTime":"0","endTime":"0","summary":"本文来源：时代财经 作者：李傲华11月22日，华领医药-B（02552.HK）发布公告称，其全资附属公司华领医药技术（上海）有限公司向拜耳医药保健有限公司（下称“拜耳”）发出书面通知，表示有意自2025年1月1日起，将用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁（多格列艾汀片，dorzagliatin）在中国的商业化责任过渡至华领...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OkZRfC7iHWXV1IqnhMbRdjH85S5bw_Jx9PhB3lHQX5cUEAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OkZRfC7iHWXV1IqnhMbRdjH85S5bw_Jx9PhB3lHQX5cUEAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241122A08YQW00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241122A08YQW00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2485523380","title":"华领医药-B11月22日遭主力抛售285万元 环比增加427.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485523380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485523380?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:16","pubTimestamp":1732263364,"startTime":"0","endTime":"0","summary":"11月22日, 华领医药-B股价跌15.38%，报收1.32元，成交金额2700万元，换手率1.92%，振幅16.67%，量比11.44。华领医药-B今日主力资金净流出285万元，连续3日净流出，上一交易日主力净流出54万元，今日环比增加427.78%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为1.97%。该股近5个交易日下跌17.50%，主力资金累计净流出391万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出237万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161639a24d6548&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161639a24d6548&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2485827902","title":"华领医药独苗产品结束与拜耳合作，谁会接盘？","url":"https://stock-news.laohu8.com/highlight/detail?id=2485827902","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485827902?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:32","pubTimestamp":1732260742,"startTime":"0","endTime":"0","summary":"自本公告日期起至终止生效日期止，拜耳与华领医药将继续履行现有协议直至终止。另外，华领医药还可能寻求其他潜在合作伙伴继续多格列艾汀的商业化。二者合作期间，华领医药收到拜耳的里程碑款项合计已达到15亿元。而截止发稿，华领医药未就此事作出回应。华领医药在2024年中报中表示，其目标是2025年实现盈利。华领医药表示，其专注于FDC新候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122153402a24d4b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122153402a24d4b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2485245477","title":"华领医药-B(02552)：自2025年1月1日起终止拜耳华堂宁®代理销售权","url":"https://stock-news.laohu8.com/highlight/detail?id=2485245477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485245477?lang=zh_cn&edition=full","pubTime":"2024-11-22 10:05","pubTimestamp":1732241110,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月22日，华领医药-B公布，公司向拜耳医药保健有限公司发出书面通知，表示有意自2025年1月1日起，将公司开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至公司。为实现过渡，公司有权并计划自2025年1月1日起终止协议。据了解，华领医药与拜耳于2020年8月17日签署关于华堂宁 的战略合作协议。截至目前，华领医药收到拜耳的里程碑款项合共已达到15亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2485472677","title":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2485472677","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485472677?lang=zh_cn&edition=full","pubTime":"2024-11-22 09:48","pubTimestamp":1732240139,"startTime":"0","endTime":"0","summary":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作* 专注开发2型糖尿病药物的华领医药2552.HK周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。* 该公司稍早公布，已向拜耳BAYGn.DE发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至该公司。为支持华堂宁在中国的持续商业销售，该公司可能会寻求其他潜在合作伙伴。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT03R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02552","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huamedicine.com","stockEarnings":[{"period":"1week","weight":0.02},{"period":"1month","weight":-0.0192},{"period":"3month","weight":0.3304},{"period":"6month","weight":-0.0613},{"period":"1year","weight":-0.2073},{"period":"ytd","weight":-0.2234}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力於开发用於治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。该公司主要在国内外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.009978},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.055195},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104259},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.047122},{"month":5,"riseRate":0.5,"avgChangeRate":0.063673},{"month":6,"riseRate":0.5,"avgChangeRate":0.0552},{"month":7,"riseRate":0.333333,"avgChangeRate":0.009836},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.059642},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.002881},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.089836},{"month":11,"riseRate":0.571429,"avgChangeRate":0.087456},{"month":12,"riseRate":0.714286,"avgChangeRate":0.056685}],"exchange":"SEHK","name":"华领医药-B","nameEN":"HUA MEDICINE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华领医药-B,02552,华领医药-B股票,华领医药-B股票老虎,华领医药-B股票老虎国际,华领医药-B行情,华领医药-B股票行情,华领医药-B股价,华领医药-B股市,华领医药-B股票价格,华领医药-B股票交易,华领医药-B股票购买,华领医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}